THE POWERWAND™

UNDISPUTED BEST IN CLASS

ZERO BSI

36,000 CATHETER-DAYS

BLOOD DRAWABLE
60-99%

COMPLETION OF THERAPY
79-97%

PATIENT SATISFACTION
98-100%

$448k
ANNUAL SAVINGS IN ONE ICU & 1-2 LIVES SAVED

$531.5k
ANNUAL SAVINGS IN MAGNET® RECOGNIZED TEACHING HOSPITAL

$90
SAVINGS PER INSERTION

access scientific
# PEER REVIEWED PUBLICATIONS

## ANNALS OF PHARMACOTHERAPY 2019
- ZERO bloodstream infections (BSIs) in 1005 catheter-days
- POWERWAND can be successfully used with OPAT patients
- No severe complications associated with the use of vancomycin

## AJIC 2019
- For 2 years, ZERO infections were recorded with the POWERWAND – over 5,430 catheter-days
- POWERWAND is only vascular access device in hospital system to never be associated with an infection
- PICC placements reduced by 35%
- Estimated 10 CLABSI avoided and 1 patient death

## MEDICAL DEVICES: EVIDENCE AND RESEARCH 2018
- 5 times more bacteria were able to attach and grow on the control polyurethane material than on the POWERWAND (P=0.0020)
- The few bacteria that were able to attach to the POWERWAND catheter material had a 1.5 times greater likelihood of dying

## JAVA 2017
- 5 years of data proving vancomycin (4mg/mL) can safely and cost-efficiently be administered through POWERWAND
- ZERO bloodstream infections (BSIs) in 8,145 catheter-days
- 2.7% total complication rate

## JAVA 2015
- ZERO BSIs
- 88 – 100% reduction of central line bloodstream infections (CLABSI) in two hospitals
- 58% reduction in PICC placements
- Estimated $531,570 in annual savings

## INFECTIOUS DISEASES IN CLINICAL PRACTICE 2015
- ZERO BSIs for 12 months (3.32 CLABSI rate previously)
- 37% reduction in central line catheter days
- Translates to $448,000 annual savings and 1-2 lives saved

## JOURNAL OF VASCULAR ACCESS 2014
- POWERWANDs effectively replace PICCs for administration of short term vancomycin
- ZERO BSIs
- ZERO phlebitis
- ZERO thrombosis
- $90.00 savings per insertion

## JAVA 2012
- ZERO BSIs
- 88.5% completion of therapy (note: PICCs = 72-73%)
- Patient Satisfaction – 98%
- Average catheter dwell time – 6.8 days

---

# SCIENTIFIC POSTERS

## INS ANNUAL SCIENTIFIC MEETING 2016
- POWERWAND safe for long-term administration of vancomycin (4mg/mL)
- ZERO BSIs in 264 catheter-days
- 8.3% complication rate

## AMERICAN BURN ASSOCIATION NATIONAL CONFERENCE 2014
- POWERWAND reduced PIV sticks and supply costs
- Decreased nursing time (3.5 – 5.3 hours per patient)
- ZERO BSIs
- Patient Satisfaction – 100%
- Average catheter dwell time – 8.8 days

## INS ANNUAL SCIENTIFIC MEETING 2013 (2 POSTERS)
- ZERO BSIs in 8,426 catheter-days
- 93% completion of therapy
- 99% full length of stay blood draw (occasionally used Cath-Flo™ off-label)
- ZERO BSIs in 617 catheter-days
- 87.5% completion of therapy
- 68% Blood draw

## AVA ANNUAL SCIENTIFIC MEETING 2012 (2 POSTERS)
- ZERO BSIs in 477 catheter-days
- 97% completion of therapy
- 60% Blood draw for full length of stay
- ZERO BSIs in 624 catheter-days
- 84% full length of stay blood draw (used heparin lock)